We cant just hand them out like candy, says Dr
Retatrutide Safety Data: Gastrointestinal events: 34% incidence (mild-moderate) Hypoglycemia risk: 2.1% severe events Injection site reactions: 8.7% Cardiovascular events: 0.9% Pancreatitis risk: 0.2% Semaglutide Safety Data: Gastrointestinal events: 44% incidence (mild-moderate) Hypoglycemia risk: 3.2% severe events Injection site reactions: 12.4% Cardiovascular events: 1.2% Pancreatitis risk: 0.3% The reduced gastrointestinal adverse event profile of retatrutide potentially results from its balanced receptor activation approach, minimizing excessive GLP-1 stimulation while maintaining therapeutic efficacy.If you need peptide APIs with improved tolerability profiles for sensitive patient populations, then retatrutide offers enhanced safety characteristics compared to traditional GLP-1 agonists
Foundayo (Orforglipron) Newly approved in April 2026, Foundayo is another wonderful choice for those needing flexibility
This might mean changing diets, taking supplements, or undergoing other treatments
This reduces the chance of side effects like nausea, vomiting, diarrhea, constipation, and reflux
Small Rumin Res